EurekAlert!22d
FXR cyclic peptide antagonists as a novel strategy for MASH treatment
Current endogenous or synthetic FXR antagonists, such as glyco-ursodeoxycholic acid, target the LBP by competitively blocking the binding of FXR-activating bile acids like chenodeoxycholic acid ...
pharmaphorum1mon
FDA clears first therapy for rare disease CTX from Mirum
The drug is based on chenodeoxycholic acid (CDCA), a naturally occurring bile acid, which has been approved in Europe to treat CTX for several years. In the US it has been used for many years ...
Hosted on MSN20d
Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH
Current endogenous or synthetic FXR antagonists, such as glyco-ursodeoxycholic acid, target the LBP by competitively blocking the binding of FXR-activating bile acids like chenodeoxycholic acid ...
Yahoo Finance1mon
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
In CTX, a deficiency of the bile acid chenodeoxycholic acid (CDCA) leads to a buildup of bile alcohols which precedes a toxic accumulation of cholestanol. Cholestanol is the key driver of symptomatic ...